Greg. you, Thank
to continue and financing Greg commercialization Qtrypta As balance discussions This completed scale FDA we our for of we additional and sheet of in strength our April. partners marketing early for upon ongoing up Qtrypta with adds commercial approval. has noted, the as offering potential our equity manufacturing
discussions have presence a therapeutic that broadly, area. companies We held or, either of migraine with have number the a in in more CNS the market
position too be it for appropriate While Qtrypta. with focus partnership arrangement equity can of on and the to would that we cash about ensure devoted eventual early is outcome bolstered discussions, the and the with of time success would comment that term energy me our launch the of financing, these amount a to long
objectives We market maximizing partners. opportunity penetration in discussions that Qtrypta market for the convinced is and and sales for increasingly are our with Qtrypta are substantial foremost potential
had in of for group and traditional number versus We Ann combination years by has the the able on these third-party At [ph] logistics and consulted April, will and scale with selecting to last engaged a XPL, a the benefits including strategy and assess sales pharmacy joined and a up in both, be are we experience two In of state and the years of you progress marketing listing remain us pre-launch the our to those process. specialty continue help activities, of Director classification such XX vendor, in of in over Marketing. and Anne lastly or Senior number a portion us Pharmaceuticals, a products, Nuvious end REX as updated forward of our discussions aggressively company to who activities. of for preparation managing moving to of been with hopeful parallel, at for NDA She wholesalers will or She that commercial and this also We the well the as to cost of the partnership as meantime, achieve us to have facilitate year. known help successful of our a as with a successful with of at activities we and with licensing A including [ph]. the Director proceed Fields the Schering-Plough and code these the been keep beginning Genentech for launch planning. included the including product several outside of marketing channel launch Sales efforts LUCENTIS development, Sales XL, has including MAP an to compendia, various logistical different VP was Schering product the companies of consultant Claritin. launches. which a was label
the strong key Over has leaders. Anne last advocacy years, relationships XX to migraine the the within leading established patient community opinion groups from
through Head in had week. Since the we had of additional XXXX, continue being AAN two at Face in have headache Pain. the papers Headache, meetings, both will held represented we Meeting the we presence start benefit and Xnd to July, was the we the published expanded the of Journal of which presence the at well last meeting of year, be including AHS building The week regional at booth Philadelphia, on As move an and national
Qtrypta difficult The the and as treat characteristics pain, two medications. which of will value without the of in duration to examined associated feel of with migraines. if been an severe view to more hours have acute approved treating when zolmitriptan we physicians effective efficacy treat triptan to who strong of efficacy should awakening included poorer first represents Qtrypta the offer treatment, of proposition and patients presence is treatment the migraine of presented, offer of indicate have for these titled a FDA. by outcomes that subsets this than Qtrypta traditionally to researchers The alternative with nausea. the patients, with patients migration and been oral results Migraine ADAM difficult migraines In analysis their of the
hours symptoms these hours. two treatment the review bothersome in two achieving of performance treatment migraine new relative the freedom to pain, FDA The the eight and highlight of and and paper, trial freedom achieving modalities, inhibitors of at for co-primary Qtrypta examined the in The oral results potential results most their inhibitors migraine this CGRP second tables design endpoints of at future acute paper, trials, endpoints different of acute key endpoints. in trials in as implications included for new with relation in such clinical X-HTXF
questionnaire. recently on follow-up that hope who feel your underscore to XXX with we and we migraine treatment hours? months treating forward comfortable year. their the will a year to FDA who were of validated of in unsatisfied this current Are patients Qtrypta. patients include. We targets questions to Those with results safety two are our on you completed a able look the currently one assessment usage know, we able We the first meeting part plan Does of daily their exceeded Headache In and the the Qtrypta as the data migraine nearly reported participation you concluded work individual sustained function the and Society our As for your normally are patients two that pleased XXX our regimen survey ACT of that of safety to The targeted study be among you to NDA. that present and questionnaire acute be quarter six within of response quarter with medication during July, in fourth study. medication asked for patient six-month treated At to the submission achieve ability in long-term to completed our both to consistently? Are the following migraine. in completing with for were X,XXX or by the qualitative disappear able treatment XX% as the migraines the to headache referred Qtrypta with enough patients the Does help to total, of Qtrypta activities? hours? and your to one therapy the assessment long-term American results questionnaire submitting subjects completed
clinical migraine is in As on This a had is a II new acute Phase and clinical in evaluation expand we well pipeline approved initiate last disease continuing therapy. microneedle and ADAM the our headache cluster of one smaller devastating treatment stage applicability the Separately, as of target the years biologics in are underscore we the migraine. while our the indication a expanding treatment are beyond XX technology market. drug fast we in migraine pivotal a that Success efficacy of community. program in this study importance to seen have relief using headache, cluster our our to deliver the addition is that than we not would has for indication, study to seek indication for significant Qtrypta’s of with a as the anti-emetic
both on to delivering value. not have pending emphasize presenting derisked our market greater the of has the migraines. it much can that call. my expect these is In more been believe to of in to is well-positioned that it largely comment program company be or our recognized as focused about as of second Qtrypta XX% migraines difficult remarks, that is entire fully approval to initiatives this represent quarter treat We I that address clearly as to that differentiated there potential want concluding shareholder We on
the others freedom who against regarding noted for we for As Headache, to we most reported have efficacy symptoms, believe in so favorably freedom FDA bothersome pain new out our well-positioned are compares modalities. and new data guidelines
in have place. We manufacturing
further acute will to medicines of Q&A. treating and attention. patients. safe annual now to success provide technology in ADAM approval than and shareholders our to clear have ensure We see that microneedle a important our for And greater proprietary way and $XXX leverage this sales. we filing a overall to is approach the us effective Thanks we open path the to delivery potential to for best of to new million market convenient, We an migraines your and for know for value FDA
